The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Trimetazidine-Induced Parkinsonism: A Systematic Review
|
|---|---|
| Published in |
Frontiers in Neurology, February 2020
|
| DOI | 10.3389/fneur.2020.00044 |
| Pubmed ID | |
| Authors |
Anna Marielle B. Dy, Lorenzo Luis G. Limjoco, Roland Dominic G. Jamora |
| Abstract |
Importance: Trimetazidine (TMZ) is a medication given to patients with stable coronary artery disease. While it is reportedly well-tolerated, there are increasing numbers of reports of adverse events such as parkinsonism. Objectives: The purpose of this study was to systematically review the currently available literature on TMZ-induced parkinsonism. Evidence Review: A search of Scopus, MEDLINE, EMBASE, the Cochrane Library, the Health Technology Assessment Database, PubMed, Science Direct, and Google Scholar was conducted on or before November 7, 2019. The literature search included cohort studies, prospective and/or retrospective studies, meta-analysis, and other systematic reviews published as an original article, including abstracts and full texts. We included patients taking TMZ who developed one or more of the parkinsonian symptoms of bradykinesia, tremors, rigidity, and postural instability, where these symptoms improved after withdrawal of the said medication. Findings: There are currently five studies on TMZ use and associated parkinsonism. The literature included two case reports, one case series, and one retrospective and one prospective study. We found no results from randomized clinical trials. Overall, 88 patients developed TMZ-induced parkinsonism. Regression of parkinsonism was reported in all of the participants after withdrawal of TMZ. A total of 49 patients (55.7%) had complete regression of symptoms, while 39 patients (44.3%) had significant reduction of symptoms. The duration between TMZ (dose, 60-80 mg/day) intake and onset of symptoms ranged from 4 months to 20 years. The most commonly reported extrapyramidal symptoms were akinesia, rigidity, postural disturbances, and gait disorders, which were usually mild and symmetric. Conclusions and Relevance: The current literature suggests that TMZ can induce parkinsonism that is reversible with drug withdrawal. It is warranted to examine patients, especially the elderly, on TMZ for parkinsonian symptoms and those with pre-existing neurodegenerative diseases. Further studies are needed to assess the risk-benefit ratio of this drug, especially in the elderly age group. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 17% |
| Unknown | 5 | 83% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 13% |
| Other | 3 | 10% |
| Student > Bachelor | 2 | 7% |
| Researcher | 2 | 7% |
| Student > Ph. D. Student | 2 | 7% |
| Other | 4 | 13% |
| Unknown | 13 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
| Neuroscience | 2 | 7% |
| Computer Science | 2 | 7% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 15 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2022.
All research outputs
#2,312,882
of 23,151,189 outputs
Outputs from Frontiers in Neurology
#1,178
of 12,065 outputs
Outputs of similar age
#53,845
of 359,937 outputs
Outputs of similar age from Frontiers in Neurology
#37
of 303 outputs
Altmetric has tracked 23,151,189 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,065 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,937 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 303 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.